| FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript |
FibroGen, Inc. (NASDAQ:FGEN ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - Chief Executive Officer David DeLucia - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Matthew Keller - H.C. Wainwright Operator Good day and thank you for standing by. |
seekingalpha.com |
2025-05-13 02:31:10 |
Czytaj oryginał (ang.) |
| FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates |
FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2025-05-12 22:20:46 |
Czytaj oryginał (ang.) |
| FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update |
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2025 and provided an update on the company's recent developments. |
globenewswire.com |
2025-05-12 20:02:00 |
Czytaj oryginał (ang.) |
| Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen) |
Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights Companies and academics are working to assess challenges and seek opportunities that could influence R&D Duchenne Muscular Dystrophy. The therapies under development are focused on novel approaches to treat/improve Duchenne Muscular Dystrophy. Duchenne Muscular Dystrophy Emerging Drugs |
globenewswire.com |
2025-05-08 08:24:00 |
Czytaj oryginał (ang.) |
| FibroGen to Report First Quarter 2025 Financial Results |
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. |
globenewswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference |
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. |
globenewswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript |
FibroGen, Inc. (NASDAQ:FGEN ) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - CEO David DeLucia - CFO Conference Call Participants Andy Sieh - William Blair Matthew Keller - H.C. Wainwright Operator Hello everyone, and welcome to the FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-17 22:18:47 |
Czytaj oryginał (ang.) |
| FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results |
SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2024 and provided an update on the company's recent developments. |
globenewswire.com |
2025-03-17 18:05:00 |
Czytaj oryginał (ang.) |
| FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results |
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. |
globenewswire.com |
2025-03-03 18:45:00 |
Czytaj oryginał (ang.) |
| Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million |
FibroGen Inc. FGEN stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc AZN for approximately $160 million. |
benzinga.com |
2025-02-20 15:08:04 |
Czytaj oryginał (ang.) |
| FibroGen sells China unit to AstraZeneca in deal worth $160 million |
FibroGen said on Thursday that it has sold its China unit to AstraZeneca for about $160 million. |
reuters.com |
2025-02-20 08:40:43 |
Czytaj oryginał (ang.) |
| FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million |
SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the sale of its China subsidiary to AstraZeneca for approximately $160 million. |
globenewswire.com |
2025-02-20 08:30:00 |
Czytaj oryginał (ang.) |
| FibroGen Appoints David DeLucia as Chief Financial Officer |
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. |
globenewswire.com |
2024-12-16 10:05:00 |
Czytaj oryginał (ang.) |
| FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript |
FibroGen, Inc. (NASDAQ:FGEN ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A & IR Thane Wettig - CEO Juan Graham - CFO Conference Call Participants Andy Hsieh - William Blair Operator Good day and welcome to the FibroGen Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2024-11-12 22:38:05 |
Czytaj oryginał (ang.) |
| FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates |
FibroGen (FGEN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.52 per share a year ago. |
zacks.com |
2024-11-12 21:15:55 |
Czytaj oryginał (ang.) |
| FibroGen Reports Third Quarter 2024 Financial Results |
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company's recent developments. |
globenewswire.com |
2024-11-12 18:05:00 |
Czytaj oryginał (ang.) |
| FibroGen to Report Third Quarter 2024 Financial Results |
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. |
globenewswire.com |
2024-11-04 18:05:00 |
Czytaj oryginał (ang.) |
| FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript |
FibroGen, Inc. (NASDAQ:FGEN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia - CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig - Chief Executive Officer Deyaa Adib - Chief Medical Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President, China Operations Conference Call Participants Dalton Greenwood - William Blair Dina Ramadane - Bank of America Paul Choi - Goldman Sachs Operator Good day and welcome to the FibroGen Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. |
seekingalpha.com |
2024-08-09 15:32:04 |
Czytaj oryginał (ang.) |
| FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates |
FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.65 per share a year ago. |
zacks.com |
2024-08-06 23:15:46 |
Czytaj oryginał (ang.) |
| One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program |
FibroGen Inc. FGEN saw its share price plummet after the release of topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in pancreatic cancer patients. |
benzinga.com |
2024-07-31 16:33:56 |
Czytaj oryginał (ang.) |
| FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts |
FibroGen (NASDAQ: FGEN ) layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. FibroGen says that it is going into a cost-saving mode that will result in layoffs for 75% of its U.S. employees. |
investorplace.com |
2024-07-31 14:01:47 |
Czytaj oryginał (ang.) |
| Why Is FibroGen (FGEN) Stock Down 44% Today? |
FibroGen (NASDAQ: FGEN ) stock is falling hard on Wednesday after the biopharmaceutical company reported results from failed clinical trials. The first failed clinical trial covers the treatment of metastatic pancreatic cancer with pamrevlumab. |
investorplace.com |
2024-07-31 12:31:04 |
Czytaj oryginał (ang.) |
| FibroGen to Report Second Quarter 2024 Financial Results |
SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. |
globenewswire.com |
2024-07-30 20:07:00 |
Czytaj oryginał (ang.) |
| FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials |
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen's immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors. |
globenewswire.com |
2024-06-03 20:05:00 |
Czytaj oryginał (ang.) |
| FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors |
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. |
globenewswire.com |
2024-06-03 20:02:00 |
Czytaj oryginał (ang.) |
| 7 Penny Biotech Stocks to Triple Your Investment |
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. |
investorplace.com |
2024-05-28 10:10:00 |
Czytaj oryginał (ang.) |
| FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting |
SAN FRANCISCO, May 23, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study conducted by the University of California San Francisco of FG-3246 (FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with a MMAE-containing payload, in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. |
globenewswire.com |
2024-05-23 21:05:00 |
Czytaj oryginał (ang.) |
| FibroGen to Participate in Upcoming Investor Conferences |
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company's management will participate in the following investor conferences: |
globenewswire.com |
2024-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript |
FibroGen, Inc. (NASDAQ:FGEN ) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A and IR Thane Wettig - CEO Deyaa Adib - CMO Juan Graham - CFO Chris Chung - SVP, China Operations Conference Call Participants Andy Hsieh - William Blair Paul Choi - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the FibroGen's First Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-05-07 02:31:06 |
Czytaj oryginał (ang.) |
| FibroGen Reports First Quarter 2024 Financial Results |
SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2024 and provided an update on the company's recent developments. |
globenewswire.com |
2024-05-06 20:02:00 |
Czytaj oryginał (ang.) |
| FibroGen to Report First Quarter 2024 Financial Results |
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. |
globenewswire.com |
2024-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting |
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois. |
globenewswire.com |
2024-04-24 20:02:00 |
Czytaj oryginał (ang.) |